Straight Path Wealth Management Takes $435,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Straight Path Wealth Management purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 4,706 shares of the biopharmaceutical company’s stock, valued at approximately $435,000.

Several other hedge funds also recently made changes to their positions in the stock. HHM Wealth Advisors LLC boosted its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences during the fourth quarter valued at $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 8,500 shares of the business’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now owns 132,373 shares in the company, valued at $12,173,021.08. The trade was a 6.03 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 in the last 90 days. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 0.6 %

Shares of NASDAQ:GILD opened at $115.44 on Thursday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $117.39. The company has a market cap of $143.87 billion, a PE ratio of 312.00, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock’s 50-day moving average is $98.71 and its 200 day moving average is $90.91.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.74%. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Bank of America lifted their price objective on Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group lifted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Citigroup began coverage on Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price objective for the company. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Finally, The Goldman Sachs Group lifted their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.24.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.